INTRODUCTION
============

*Stenotrophomonas maltophilia* is a non-fermentative gram-negative bacillus found extensively in the environment and has emerged as an important nosocomial pathogen \[[@B1], [@B2]\]. *S. maltophilia* causes a variety of nosocomial infections, particularly pneumonia and bacteremia in severely debilitated or immunosuppressed patients with underlying chronic diseases who are admitted to intensive care units. Its infamy is partly attributable to its characteristic resistance to most of the currently available broad-spectrum antimicrobial agents and partly to its ability to rapidly proliferate a multiresistant phenotype \[[@B3]-[@B5]\].

*S. maltophilia* has high intrinsic resistance to a variety of structurally unrelated antimicrobial agents, including β-lactams, aminoglycosides, and quinolones. In part, the resistance of *S. maltophilia* to multiple antimicrobial agents can be attributed to limited outer membrane permeability and active antimicrobial efflux; 2 Sme efflux systems, smeABC and smeDEF, have been identified in this organism \[[@B6]-[@B8]\]. The mechanisms underlying antimicrobial drug resistance in clinical isolates have proven problematic in the treatment of *S. maltophilia* infections. The recently developed multilocus sequence typing (MLST) technique appears to be a reliable tool for tracking the source of infection and the distribution of pathogens isolated from hospitalized patients; this technique provides consistent epidemiological data, and the results from different laboratories can be compared because the international databases are easily accessible \[[@B9]-[@B11]\].

The objectives of the present study were to correlate the antimicrobial resistance patterns of the *S. maltophilia* isolates with their antimicrobial efflux mechanisms and to determine the genetic characteristics of *S. maltophilia* isolates that are responsible for their current epidemic status.

METHODS
=======

1. Bacterial isolates and antimicrobial susceptibility tests
------------------------------------------------------------

In total, 33 consecutive, non-duplicated *S. maltophilia* isolates were obtained from patients in a tertiary hospital in Daejeon, Korea between January and December 2009. Biochemical profiling using conventional methods and the Vitek 2 system (BioMérieux, Hazelwood, MO, USA) for microbial identification were used to confirm that the isolates were *S. maltophilia*.

In the antimicrobial susceptibility tests, minimum inhibitory concentration (MIC) was determined by using the agar dilution method and an E-test conducted in accordance with the guidelines of the CLSI \[[@B12], [@B13]\]. The susceptibility of *S. maltophilia* to the following antimicrobial agents was tested: ceftazidime (Hanmi, Seoul, Korea), cefepime (Boryung, Seoul, Korea), ticarcillin/clavulanic acid, meropenem, aztreonam, trimethoprim/sulfamethoxazole (bioMérieux, Marcy I\'Etoile, France), amikacin, gentamicin, levofloxacin, minocycline (Sigma Chemical Co., St Louis, MO, USA), and ciprofloxacin (Fluka, Buchs, Switzerland). *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used for quality control purposes.

2. Real-time PCR analysis to assess the expression of the Sme efflux system
---------------------------------------------------------------------------

Cell suspensions were prepared and inoculated in brain-heart infusion broth (Difco, Cockeysville, MD, USA). After overnight culture, total RNA was extracted from the cell suspensions by using the TRI REAGENT® (Montgomery, OH, USA). Additionally, 20 µL of cDNA was obtained from 5 µg of total RNA by using the DiaStar™ RT Kit (SolGent, Daejeon, Korea). The amplification mixtures for real-time PCR (20 µL) contained template cDNA, 2× SYBR Green I Master Mix (Applied Biosystems, Foster, CA, USA), and primers.

The sequences of the primers designed for this study were as follows: *smeB* (F: 5\'-ACCGCCCAGCTTTCATACAG-3\'; R: 5\'-GACATGGCCTACCAGGAACAG-3\') and *smeF* (F: 5\'-TCGTCCAGGCTGACATTCAA-3\'; R: 5\'-AACGCGGATCGTGATATCG-3\'). The primer sequences used for the endogenous control gene were *rDNA* (F: 5\'-TGACACTGAGGCACGAAAGC-3\'; R: 5\'-CATCGTTTAGGGCGTGGACTA-3\'). Real-time PCR reactions were performed using the StepOne real-time PCR (Applied Biosystems); the PCR cycle included the following steps: activation and denaturation step for 10 min at 95℃, 40 cycles of 15 sec at 95℃, and annealing and extension for 1 min at 60℃. Standard curves for the expression levels of *smeABC*, *smeDEF*, and *rDNA* were constructed using the expression levels of these genes in *S. maltophilia* ATCC 13637; these standard curves were used as calibrators to normalize the relative expression levels of the *smeB* and *smeF* genes in clinical isolates. Overexpression of the Sme efflux system was assessed as described in the study of Chang et al. \[[@B7]\].

3. MLST
-------

Genomic DNA was extracted from the clinical isolates by using a Genomic DNA Prep Kit (SolGent) and was used as a template. PCR was performed using 50 ng of the template DNA (genomic DNA), 2.5 µL of 10×Taq buffer, 0.5 µL of 10 mM dNTP mix, 20 pmol of each primer, and 0.7 U of Taq DNA Polymerase (SolGent) in a total volume of 25 µL. Internal fragments of 7 housekeeping genes (*atpD*, *gapA*, *guaA*, *mutM*, *nuoD*, *ppsA*, and *recA*) were amplified in a GeneAmp PCR System 9600 (Perkin-Elmer Cetus Corp., Norwalk, CT, USA) by using the following steps: pre-denaturation of the reaction mixture for 9 min at 95℃; 30 cycles of 20 sec at 94℃, 1 min at appropriate annealing temperature, and 50 sec at 72℃; and final elongation for 5 min at 72℃ \[[@B9]\]. The amplicons were purified using a PCR Purification Kit (SolGent) and sequenced using a BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) and an ABI PRISM 3730XL DNA Analyzer (Applied Biosystems). The allele number for each gene was assigned on the basis of the information in the *S. maltophilia* MLST database (<http://pubmlst.org/smaltophilia/>). A combination of the allelic sequences of the 7 genes yielded the allelic profile for each isolate.

4. Statistical analysis
-----------------------

The data was analyzed using SPSS ver. 12.0 (SPSS, Inc., Chicago, IL, USA) with Student\'s *t* test. The differences were considered statistically significant at *P*\<0.05.

RESULTS
=======

1. The pattern of antimicrobial resistance
------------------------------------------

We tested the susceptibility of 33 clinical isolates of *S. maltophilia* to 11 antimicrobial agents on the basis of the MIC determinations ([Table 1](#T1){ref-type="table"}). *S. maltophilia* showed low susceptibility to cefepime (9.1%), meropenem (0%), and aztreonam (3.0%), which are members of the β-lactam group; however, it showed relatively high susceptibility to ceftazidime (69.7%). The susceptibility of the organism to aminoglycosides, namely, amikacin and gentamicin, was 6.1%, whereas that for ciprofloxacin (a quinolone) was 45.5%. Most of the isolates were susceptible to ticarcillin/ clavulanic acid (97.0%), levofloxacin (87.9%), trimethoprim/sulfamethoxazole (93.9%), and minocycline (97.0%).

2. Determining the overexpression of *smeABC* and *smeDEF*
----------------------------------------------------------

Real-time PCR analysis was used to assess the overexpression of the Sme efflux systems (*smeABC* and *smeDEF*), and the results of the analysis showed overexpression of *smeB* in 21 (63.6%) and *smeF* in 19 (57.5%) of the 33 clinical isolates. Fifteen (45.4%) isolates overexpressed both *smeB* and *smeF* ([Table 2](#T2){ref-type="table"}). After analyzing the pattern of antimicrobial resistance and the overexpression of Sme efflux systems, the MICs of ciprofloxacin (MIC~50~=4; 6.83-fold increase) and levofloxacin (MIC~50~=1; 3.60-fold increase) were found to be significantly higher for the isolates with detectable *smeB* and/or *smeF* than for the isolates without detectable *smeB* and/or *smeF*. Overexpression of the smeABC efflux pump was statistically related to the MICs of ciprofloxacin (*P*=0.033) and levofloxacin (*P*=0.034). However, the overexpression of smeDEF (CIP, *P*=0.100; LEV, *P*=0.162) alone and both smeABC and smeDEF (CIP, *P*=0.056; LEV, *P*=0.064) were not related to quinolone resistance.

3. MLST analysis
----------------

In the MLST analysis of the 33 *S. maltophilia* isolates, 3 sequence types (STs) (ST5, ST28, and ST31) and 23 diverse allelic profiles were detected ([Table 1](#T1){ref-type="table"}). The most common form of allelic profile was 19, 5, 14, 8, 5, 26, 4 (4 isolates); the other forms were ST31 (3, 4, 24, 7, 7, 22, 7; 2 isolates), ST5 (5, 22, 9, 4, 27, 5, 7; 2 isolates), 8, 20, 10, 25, 14, 17, 3 (2 isolates), and 2, 13, 42, 20, 30, 27, 20 (2 isolates).

The NJ tree model was chosen for representing the findings of the cluster analysis of all 33 *S. maltophilia* strains ([Fig. 1](#F1){ref-type="fig"}).

DISCUSSION
==========

*S. maltophilia* was first reported in the early 1970s, and since then, it has continued to spread through the 1990s. This spread can be attributed to the widespread use of chemotherapy and broad-spectrum antimicrobial agents as well as to the adoption of highly invasive medical practices \[[@B14]\]. Among the clinically important bacteria isolated from major hospitals in Korea, *S. maltophilia* had isolation rates of 1.8% in 1998 and 3.1% in 2005 and 2006; these isolation rates are indicative of a serious problem of nosocomial infection \[[@B15], [@B16]\].

*S. maltophilia* is intrinsically resistant to multiple antimicrobial agents, including β-lactams, aminoglycosides, carbapenems, and quinolones; clinical isolates of *S. maltophilia* frequently exhibit high multidrug resistance. In this study, 33 *S. maltophilia* isolates were found to be highly resistant to β-lactams and aminoglycosides; these organisms showed a ciprofloxacin susceptibility rate of 45.5%. According to the findings of a survey conducted in Korea between 2000 and 2003, the rate of ciprofloxacin resistance was approximately 10% \[[@B17]\]. However, in this study, the organism showed a significant 3-fold increase in drug resistance.

Although various mechanisms for antimicrobial drug resistance have been reported in clinical isolates of *S. maltophilia* thus far, little information is available about this species in Korea. Recently, antimicrobial efflux mechanisms have been increasingly recognized as major factors in the intrinsic and acquired resistance of many significant human pathogens, including *Pseudomonas aeruginosa* and *Burkholderia cepacia*. In particular, antimicrobial efflux systems (including MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM) belonging to the resistance-nodulation-division family, which contribute to multidrug resistance have been characterized in *P. aeruginosa* \[[@B18]-[@B20]\]. Additionally, overexpression of the smeABC and SmeDEF efflux pumps in *S. maltophilia* contributes to intrinsic multidrug resistance and plays an important role in the resistance characteristics of clinical isolates. There have been reports that the overexpression of the Sme efflux system of *S. maltophilia* induced resistance to several antimicrobial agents, including β-lactams, aminoglycosides, and quinolones \[[@B6], [@B7], [@B21], [@B22]\]. We found that the overexpression rates of *smeB* and *smeF* were 63.6% and 57.4%, respectively, in organisms with high resistance to β-lactams and aminoglycosides. A study conducted in Taiwan in 2004 indicated that the smeABC efflux pumps might play a role in the ciprofloxacin resistance of *S. maltophilia* \[[@B7]\]. In this study, 21 isolates with *smeB*, which was detected using real-time PCR analysis, showed a 6.83-fold and 3.60-fold increase in the MICs of ciprofloxacin and levofloxacin, respectively. The MIC of ciprofloxacin in our study was 3-fold higher than that in a previous Taiwanese report (2.16-fold). Thus, we suggest that the overexpression of smeABC was associated with high MIC values for ciprofloxacin (*P*=0.033) and levofloxacin (*P*=0.034). However, the overexpression of SmeDEF (CIP, *P*=0.100; LEV, *P*=0.162) alone and both smeABC and SmeDEF (CIP, *P*=0.056; LEV, *P*=0.064) were not related to quinolone resistance.

MLST for molecular epidemiologic studies of *S. maltophilia* is a recently developed strain-typing system that focuses strictly on conserved housekeeping genes. In previous studies in Korea, this genetic relationship was evaluated using pulsed-filled gel electrophoresis (PFGE) after *Xba*I digestion or molecular typing by using enterobacterial repetitive intergenic consensus (ERIC)-PCR and random amplified polymorphic DNA (RAPD) \[[@B17], [@B23]\]. It is thought that phylogenetic studies of *S. maltophilia* by using MLST will contribute significantly to a new perspective on the molecular epidemiology of *S. maltophilia*. We applied MLST analysis to 33 strains and found that most of the strains represent 3 STs (ST5, ST28, and ST31) as well as 23 new allelic profiles. Similarly, studies in Spain in 2004 and in Korea in 2010 showed a high degree of genetic diversity among *S. maltophilia* isolates despite their origin in a single hospital \[[@B5], [@B23]\]. This finding indicates that *S. maltophilia* has a high potential for environmental distribution. In the *S. maltophilia* MLST database (<http://www.pubmlst.org/smaltophilia/>), 56 STs have been reported thus far, of which ST5, ST28, and ST31 have been identified in Korea. Database analysis shows that there are considerably fewer STs for *S. maltophilia* isolates than other bacterial isolates.

A distinct finding of our study was the relationship between quinolone resistance and the overexpression of the smeABC efflux system. This relationship was also observed in some parts of the MLST cluster. The group A and A\' isolates shown in [Fig. 1](#F1){ref-type="fig"} were highly resistant to ciprofloxacin and harbored *smeB*, as observed in the real-time PCR analysis. Additionally, the group B isolates were highly resistant to ceftazidime and cefepime ([Fig. 1](#F1){ref-type="fig"}). A similar relationship exists between the clonal complex 17 (CC17) and antimicrobial resistance of *Enterococcus faecium*. CC17 was defined by using an MLST assay and is regarded as excellent example of cumulative evolutionary processes. In the majority of the *E. faecium* isolates, CC17 is characterized by ampicillin and quinolone resistance as well as the presence of a putative pathogenicity island, including the *esp* gene \[[@B24], [@B25]\].

The incidence of *S. maltophilia* infections has increased worldwide, but only a few studies on this topic have been performed in Korea thus far. On the basis of the findings of the MLST assays for *S. maltophilia*, we found that antimicrobial resistance correlated with the overexpression of the Sme efflux systems.
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![A phylogenetic tree of the concatenated nucleotide sequences of 7 housekeeping genes (*atpD*, *gapA*, *guaA*, *mutM*, *nuoD*, *ppsA*, and *recA*) of *S. maltophilia* obtained using the NJ method with Kimura 2 correction for distance calculations. Group A and A\' isolates were highly resistant to ciprofloxacin and overexpressed *smeB*, and Group B isolates were highly resistant to ceftazidime and cefepime.](alm-32-38-g001){#F1}
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MLST, antimicrobial susceptibility, and mRNA expression studies for the 33 *Stenotrophomonas maltophilia* isolates
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Abbreviations: MLST, multilocus sequence typing; MIC, minimum inhibitory concentration; CAZ, ceftazidime; FEP, cefepime; TIM, ticarcillin/clavulanic acid; MEM, meropenem; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; MIN, minocycline.
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Correlation between antimicrobial susceptibility and the expression of *smeABC* and *SmeDEF* in *Stenotrophomonas maltophilia*
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Abbreviations: MIC, minimum inhibitory concentration; CAZ, ceftazidime; FEP, cefepime; TIM, ticarcillin/clavulanic acid; MEM, meropenem; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; MIN, minocycline.
